Chemotherapy for recurrent cervical cancer

被引:56
|
作者
Cadron, Isabelle [1 ]
Van Gorp, Toon [1 ]
Amant, Frederic [1 ]
Leunen, Karin [1 ]
Neven, Patrick [1 ]
Vergote, Ignace [1 ]
机构
[1] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Obstet & Gynecol, Div Gynecol Oncol, B-3000 Louvain, Belgium
关键词
recurrent cervical cancer; chemotherapy; cisplatin;
D O I
10.1016/j.ygyno.2007.07.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To give an overview of chernotherapy schemes used in recurrent cervical cancer. Methods. A pubmed search was performed using chemotherapy and recurrent cervical cancer including articles until April 2007. Results. Most recent articles and articles of interest are discussed. Conclusion. Single agent cisplatin (50 mg/m(2)) remains the current standard for recurrent cervical cancer. Numerous chemotherapeutic agents have been tested but did not show convincing evidence of improved survival rates, except for the GOG 179 study which showed an improved survival for the combination of cisplatin and topotecan compared with single agent cisplatin. However, nearly 60% of patients in both groups received prior cisplatinum therapy as a radiosensitizer, which could be responsible for the development of platinum resistance, causing lower response and survival rates in the single platinurn group. Hence, the apparent benefit in the doublet group is maybe just a reflection from the change in primary therapy And patient population. It is hoped that current trials comparing standard therapy with other single or doublet chemotherapeutic regimens or that the use of molecular-targeted agents will give us promising therapeutic options in the future. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:S113 / S118
页数:6
相关论文
共 50 条
  • [41] CHEMOTHERAPY OF CERVICAL-CANCER
    CARLSON, JA
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1990, 33 (04): : 910 - 916
  • [42] Chemotherapy for recurrent ovarian cancer
    Kaye, SB
    LANCET, 2003, 361 (9375): : 2094 - 2095
  • [43] CHEMOTHERAPY OF CERVICAL-CANCER
    GUTHRIE, D
    CLINICS IN OBSTETRICS AND GYNAECOLOGY, 1985, 12 (01): : 229 - 246
  • [44] Neoadjuvant chemotherapy for cervical cancer
    Moore, DH
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (06) : 859 - 867
  • [45] CHEMOTHERAPY IN CERVICAL-CANCER
    GLAUBITZ, M
    VAHL, U
    GUNTER, HH
    PETRY, U
    LUCK, HJ
    KUHNLE, H
    TUMORDIAGNOSTIK & THERAPIE, 1993, 14 (06) : 209 - 219
  • [46] Neoadjuvant chemotherapy for cervical cancer
    Panopoulos, C
    BALKAN CONGRESS OF ONCOLOGY, 1996, : 25 - 28
  • [47] Chemotherapy for cervical cancer in pregnancy
    de Oliveira, Aline Figueredo
    Marquez Ferreira de Souza, Luis Ronan
    Paschoini, Marina Carvalho
    Candido Murta, Eddie Fernando
    Nomelini, Rosekeila Simoes
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2019, 39 (03) : 425 - 426
  • [48] KEYNOTE-826: PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K.
    Salman, P.
    Usta, E. Hoyos
    Yanez, E.
    Gumus, M.
    de Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S.
    Monk, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A364 - A364
  • [49] CHEMOTHERAPY IN ADVANCED PRIMARY AND RECURRENT CERVICAL-CARCINOMA
    CHOO, YC
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 1982, 20 (05) : 417 - 423
  • [50] CHEMOTHERAPY IN THE MANAGEMENT OF ADVANCED OR RECURRENT CERVICAL AND ENDOMETRIAL CARCINOMA
    THIGPEN, T
    VANCE, RB
    BALDUCCI, L
    BLESSING, J
    CANCER, 1981, 48 (02) : 658 - 665